EuroHospital Varna has been acquired by Intermedica Group
December 2025 — EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
EuroHospital Varna is the largest private hospital in the city of Varna, Bulgaria, specializing in the treatment of orthopedic, surgical, gastroenterological and urological conditions. Over the years, the hospital has built a strong reputation in Varna and throughout Northeast Bulgaria as a leading center for orthopedics and traumatology. With a team of more than 100 specialists, including leading and well-established doctors in Bulgaria, the hospital attracts patients from all over the country, as well as international patients through cooperation with leading assistance companies in Europe.
Intermedica Group is one of the leading distributors of high-technology medical devices and equipment in Bulgaria and the region, supporting hospitals, clinics and physicians in improving patient care, efficiency and cost optimization. Over the past 15 years, the group has become a preferred partner to leading medical manufacturers and more than 270 healthcare institutions.
Our role in the transaction
Oaklins’ team in Bulgaria acted as the exclusive M&A advisor to the founders of EuroHospital Varna, supporting them throughout the negotiation, due diligence and sale process.
Contacter l'équipe de la transaction
Transactions connexes
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
En apprendre plusLife & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
En apprendre plusRöntgeninstitut Aarau has been acquired by Evidia
The owners of Röntgeninstitut Aarau have sold the business to Evidia Group as part of their succession planning. The former owners will remain involved in the institute and support its future development alongside Evidia.
En apprendre plus